相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma
Alexander M. Leipold et al.
LEUKEMIA (2023)
C-X-C Motif Chemokine Receptor 4-Targeted Radioligand Therapy in Patients with Advanced T-Cell Lymphoma
Andreas K. Buck et al.
JOURNAL OF NUCLEAR MEDICINE (2023)
Commercial and business aspects of alpha radioligand therapeutics
Emanuele Ostuni et al.
FRONTIERS IN MEDICINE (2023)
Not all patients with AML over 60 years of age should be offered early allogeneic stem cell transplantation
H. Joachim Deeg
BLOOD ADVANCES (2022)
CXCR4 PET/MRI for follow-up of gastric mucosa-associated lymphoid tissue lymphoma after first-line Helicobacter pylori eradication
Marius E. Mayerhoefer et al.
BLOOD (2022)
Biokinetics and Dosimetry of 177Lu-Pentixather
Heribert Haenscheid et al.
JOURNAL OF NUCLEAR MEDICINE (2022)
Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms Using 68Ga-Pentixafor PET
Andreas K. Buck et al.
JOURNAL OF NUCLEAR MEDICINE (2022)
CXCR4-targeted theranostics in oncology
Andreas K. Buck et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
David Kegyes et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)
Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies
Boglarka Gyurkocza et al.
BLOOD (2021)
177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial
Jonathan R. Strosberg et al.
LANCET ONCOLOGY (2021)
Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT
Johannes Duell et al.
JOURNAL OF NUCLEAR MEDICINE (2021)
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
Michael S. Hofman et al.
LANCET (2021)
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Oliver Sartor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Investigation of spleen CXCR4 expression by [68Ga]Pentixafor PET in a cohort of 145 solid cancer patients
Richard Lewis et al.
EJNMMI RESEARCH (2021)
Chemokine receptor-4 targeted PET/CT with 68Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: comparison to 18F-FDG PET/CT
Qingqing Pan et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
Feasibility of CXCR4-Directed Radioligand Therapy in Advanced Diffuse Large B-Cell Lymphoma
Constantin Lapa et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Side Effects of CXC-Chemokine Receptor 4-Directed Endoradiotherapy with Pentixather Before Hematopoietic Stem Cell Transplantation
Sabine Maurer et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Rituximab-PECC induction followed by 90Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study
Pieternella J. Lugtenburg et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
The role of CXCR4 in multiple myeloma: Cells' journey from bone marrow to beyond
Tomalika Rahmat Ullah
JOURNAL OF BONE ONCOLOGY (2019)
[68Ga]Ga-Pentixafor PET/MRI for CXCR4 Imaging of Chronic Lymphocytic Leukemia Preliminary Results
Marius E. Mayerhoefer et al.
INVESTIGATIVE RADIOLOGY (2018)
Dual Targeting of Acute Leukemia and Supporting Niche by CXCR4-Directed Theranostics
Stefan Habringer et al.
THERANOSTICS (2018)
Acute Myeloid Leukemia and the Bone Marrow Niche-Take a Closer Look
Lena Behrmann et al.
FRONTIERS IN ONCOLOGY (2018)
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
J. Strosberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Treatment approaches of hard-to-treat non-Hodgkin lymphomas
Lakshminarayanan Nandagopal et al.
EXPERT REVIEW OF HEMATOLOGY (2017)
CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma
Constantin Lapa et al.
THERANOSTICS (2017)
[68Ga] Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [18F] FDG and laboratory values
Constantin Lapa et al.
THERANOSTICS (2017)
Continuous blockade of CXCR4 results in dramatic mobilization and expansion of hematopoietic stem and progenitor cells
Darja Karpova et al.
BLOOD (2017)
First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease
Ken Herrmann et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia
Peter Herhaus et al.
HAEMATOLOGICA (2016)
Differential somatostatin and CXCR4 chemokine receptor expression in MALT-type lymphoma of gastric and extragastric origin
Susann Stollberg et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2016)
Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia
Peter Herhaus et al.
HAEMATOLOGICA (2016)
Radioimmunotherapy of human tumours
Steven M. Larson et al.
NATURE REVIEWS CANCER (2015)
Role of consolidation with yttrium-90 ibritumomab tiuxetan in patients with advanced-stage follicular lymphoma
Antonio C. Sanchez Ruiz et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2014)
Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
E. Zucca et al.
ANNALS OF ONCOLOGY (2013)
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
John J. Zaknun et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)
Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared With CHOP Chemotherapy Plus 131Iodine-Tositumomab for Previously Untreated Follicular Non-Hodgkin Lymphoma: SWOG S0016
Oliver W. Press et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
90Yttrium-Ibritumomab Tiuxetan Consolidation of First Remission in Advanced-Stage Follicular Non-Hodgkin Lymphoma: Updated Results After a Median Follow-Up of 7.3 Years From the International, Randomized, Phase III First-Line Indolent Trial
Franck Morschhauser et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Chemokine receptors in gastric MALT lymphoma: loss of CXCR4 and upregulation of CXCR7 is associated with progression to diffuse large B-cell lymphoma
Alexander J. A. Deutsch et al.
MODERN PATHOLOGY (2013)
Dynamic Chemotherapy-Induced Upregulation of CXCR4 Expression: A Mechanism of Therapeutic Resistance in Pediatric AML
Edward Allan R. Sison et al.
MOLECULAR CANCER RESEARCH (2013)
CXCR4 is a good survival prognostic indicator in multiple myeloma patients
Li Bao et al.
LEUKEMIA RESEARCH (2013)
Innate Immunity Derived Factors as External Modulators of the CXCL12-CXCR4 Axis and Their Role in Stem Cell Homing and Mobilization
Mariusz Z. Ratajczak et al.
THERANOSTICS (2013)
Role of CXCR4 in the Pathogenesis of Acute Myeloid Leukemia
Amnon Peled et al.
THERANOSTICS (2013)
F-18-FDG PET in the Diagnosis and Treatment of Primary Central Nervous System Lymphoma
Nobuyuki Kawai et al.
BIOMED RESEARCH INTERNATIONAL (2013)
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia
Geoffrey L. Uy et al.
BLOOD (2012)
Radioimmunotherapy Confers Long-Term Survival to Lymphoma Patients with Acceptable Toxicity: Registry Analysis by the International Radioimmunotherapy Network
Karin Hohloch et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100
Bruno Nervi et al.
BLOOD (2009)
Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome
John M. Pagel et al.
BLOOD (2009)
Phase III Trial of Consolidation Therapy With Yttrium-90-Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma
Franck Morschhauser et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
90Y-Ibritumomab Therapy in Refractory Non-Hodgkin's Lymphoma: Observations from 111In-Ibritumomab Pretreatment Imaging
Andrei Iagaru et al.
JOURNAL OF NUCLEAR MEDICINE (2008)
Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype
Sergej Konoplev et al.
CANCER (2007)
131I-tositumomab therapy as initial treatment for follicular lymphoma
MS Kaminski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-Cell lymphoma, progressive after rituximab
SJ Horning et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma
LI Gordon et al.
CLINICAL LYMPHOMA (2004)
CXCR4 and SDF-1 expression in B-cell chronic lymphocytic leukemia and stage of the disease
J Barretina et al.
ANNALS OF HEMATOLOGY (2003)
Gemcitabine and anthracyclines in breast cancer
J Jassem
SEMINARS IN ONCOLOGY (2003)
Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma
TE Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
TE Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Pivotal study of iodine I 131 Tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas
MS Kaminski et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
分享论文
